Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 7:5:8.
doi: 10.5772/63218. eCollection 2016 Jan-Dec.

Elevated Adiponectin Antibody Levels in Sera of Patients with Atherosclerosis-Related Coronary Artery Disease, Cerebral Infarction and Diabetes Mellitus

Takaki Hiwasa  1 , Xiao-Meng Zhang  1 , Risa Kimura  1 , Mikiko Ohno  2 , Po-Min Chen  2 , Eiichiro Nishi  2 , Koh Ono  2 , Takeshi Kimura  2 , Ikuo Kamitsukasa  3 , Takeshi Wada  4 , Akiyo Aotsuka  4 , Seiichiro Mine  5   6 , Hirotaka Takizawa  7 , Koichi Kashiwado  8 , Minoru Takemoto  9 , Kazuki Kobayashi  9 , Harukiyo Kawamura  9 , Ryoichi Ishibashi  9 , Koutaro Yokote  9 , Rika Nakamura  1   10 , Go Tomiyoshi  1   10 , Natsuko Shinmen  1   10 , Hideyuki Kuroda  10
Affiliations

Elevated Adiponectin Antibody Levels in Sera of Patients with Atherosclerosis-Related Coronary Artery Disease, Cerebral Infarction and Diabetes Mellitus

Takaki Hiwasa et al. J Circ Biomark. .

Abstract

Adiponectin secreted from the adipocytes plays pleiotropic, anti-atherosclerotic roles, such as enhancement of insulin secretion and an increase in energy expenditure. The measurement of levels of circulating adiponectin is useful to evaluate the progression of atherosclerosis-related diseases, such as coronary artery disease (CAD), cerebral infarction (CI) and diabetes mellitus (DM). We examined the serum antibody levels against recombinant adiponectin protein via the amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) method. The results revealed that the antibody levels were significantly higher in patients with CAD, CI and type 2 DM, than in healthy donors. Receiver operating curve analysis showed that the sensitivity was in a range of 41-48% for CAD, CI and DM. Thus, the serum anti-adiponectin antibody levels could be a common marker for atherosclerosis-related diseases.

Keywords: Antibody Biomarker; Atherosclerosis; Cardiovascular Disease; Cerebral Infarction; Diabetes Mellitus.

PubMed Disclaimer

Conflict of interest statement

This work was performed in collaboration with Fujikura Kasei Co., Ltd. and Celish Fd Inc. RN, GT, NS and HK are employees of Fujikura Kasei Co., Ltd.

Figures

Figure 1.
Figure 1.
Comparison of serum adiponectin antibodies (adiponectin-Ab) levels between the healthy donor (HD) subjects and patients with coronary artery disease (CAD). Serum antibody levels examined by AlphalLISA are shown by a box-whisker plot (a). The box plots display the 10th, 20th, 50th, 80th and 90th percentiles. P values as compared to the HD specimens are shown. Receiver operating curve (ROC) analysis was carried out for assessing the ability of adiponectin-Abs to detect CAD (b). Numbers in the curves indicate cut-off values of marker levels and those in parentheses indicate sensitivity (left) and specificity (right). P values of ROC analysis, areas under the curve (AUC) and a 95% confidence interval (CI) are also shown.
Figure 2.
Figure 2.
Comparison of serum adiponectin-Ab levels between the HD subjects and patients with acute cerebral infarction (ACI). Serum antibody levels examined by AlphalLISA are shown by a box-whisker plot as described in the legend to Figure 1. The results were also evaluated by ROC analysis (b).
Figure 3.
Figure 3.
Comparison of serum adiponectin-Ab levels between the HD subjects and patients with type 2 diabetes mellitus (DM). Serum adiponectin-Ab levels examined by AlphalLISA are shown by a box-whisker plot as described in the legends of Figure 1 (a). The results were also evaluated by ROC analysis (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784–92. - PMC - PubMed
    1. Esfahani M, Movahedian A, Baranchi M, Goodarzi MT. Adiponectin: An adipokine with protective features against metabolic syndrome. Iran J Basic Med Sci 2015;18:430–42. - PMC - PubMed
    1. Ebrahimi-Mamaeghani M, Mohammadi S, Arefhosseini SR, Fallah P, Bazi Z. Adiponectin as a potential biomarker of vascular disease. Vasc Health Risk Manag 2015;11:55–70. - PMC - PubMed
    1. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci 2015;36:461–70. - PubMed
    1. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Card Med 2008;6:27–35. - PMC - PubMed